Clinical study of <sup>99</sup>Technetium-methylenediphosphonate in the treatment of systemic lupus erythematosus complicated with osteonecrosis of the femoral head

DUAN Congcong; SHEN Mengjia; HOU Chuanyun; JIANG Chao; XIE Changhao; WANG Tao

doi:10.16766/j.cnki.issn.1674-4152.003101

Volume 21 Issue 8

Aug. 2023

Turn off MathJax

Article Contents

Article Navigation > Chinese Journal of General Practice > 2023 > 21(8): 1275-1278

DUAN Congcong, SHEN Mengjia, HOU Chuanyun, JIANG Chao, XIE Changhao, WANG Tao. Clinical study of 99Technetium-methylenediphosphonate in the treatment of systemic lupus erythematosus complicated with osteonecrosis of the femoral head[J]. Chinese Journal of General Practice, 2023, 21(8): 1275-1278. doi: 10.16766/j.cnki.issn.1674-4152.003101

Citation:

DUAN Congcong, SHEN Mengjia, HOU Chuanyun, JIANG Chao, XIE Changhao, WANG Tao. Clinical study of ⁹⁹Technetium-methylenediphosphonate in the treatment of systemic lupus erythematosus complicated with osteonecrosis of the femoral head[J]. Chinese Journal of General Practice, 2023, 21(8): 1275-1278. doi: 10.16766/j.cnki.issn.1674-4152.003101

Citation:

PDF( 1133 KB)

Clinical study of ⁹⁹Technetium-methylenediphosphonate in the treatment of systemic lupus erythematosus complicated with osteonecrosis of the femoral head

doi: 10.16766/j.cnki.issn.1674-4152.003101

DUAN Congcong¹
, SHEN Mengjia¹
, HOU Chuanyun¹
, JIANG Chao¹
, XIE Changhao^{1, 2}
, WANG Tao^{1, 2
,
,}

1.
Department of Rheumatology and Immunology, the First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, China

Funds:

2108085MH258

2020byzd060

Received Date: 2023-02-28
Available Online: 2023-09-13

Abstract

Abstract

Objective To investigate the efficacy and safety of ⁹⁹Technetium-methylenediphosphonate (⁹⁹Tc-MDP) in the treatment of systemic lupus erythematosus (SLE) complicated with osteonecrosis of the femoral head (ONFH). Methods A total of 60 patients diagnosed with SLE combined with ONFH (necrosis group) and SLE without ONFH (control group) were selected from June 2021 to September 2022 in the First Affiliated Hospital of Bengbu Medical College. Among them, the necrosis group (30 cases) was divided into the conventional group (15 cases) and the combined group (15 cases) according to whether ⁹⁹Tc-MDP was used. The concentrations of plasma osteoprotegerin (OPG) and osteopontin (OPN) were determined by ELISA before and after a short course of treatment between the combined group and the conventional group, and the control group were compared. Follow-up was conducted after a long course of treatment between the combination group and the conventional group, and the Harris score, imaging changes and adverse reactions were compared. Results There was no significant difference in baseline data between the three groups before treatment. After 1 short course of treatment: compared with before treatment, plasma OPG level increased and OPN level decreased in combination group after treatment, the differences were statistically significant. After 1 course of treatment: (1) The Harris score of hip function in the combined group was increased compared with the conventional group, and was significantly increased after treatment in the combined group compared with before treatment, the difference was statistically significant; There was no significant difference in Harris score between the conventional group after treatment and before treatment. (2) There was no significant improvement in imaging evaluation after ⁹⁹Tc-MDP treatment. (3) No serious adverse reactions were found in the three groups. Conclusion On the basis of routine medication, ⁹⁹Tc-MDP has good clinical effect and high safety in the treatment of systemic lupus erythematosus complicated with osteonecrosis of the femoral head.
- ⁹⁹Technetium-methylenediphosphonate,
- Systemic lupus erythematosus,
- Osteonecrosis of the femoral head,
- Osteoprotegerin,
- Osteopontin

FullText(HTML)

References(17)

References

[1]	张莉莉, 张冬梅, 谢长好. 初发系统性红斑狼疮相关血小板减少症的临床特点及治疗随访分析[J]. 中华全科医学, 2021, 19(5): 760-762, 793. doi: 10.16766/j.cnki.issn.1674-4152.001910 ZHANG L L, ZHANG D M, XIE C H. Clinical characteristics, treatment and follow-up analysis of newly diagnosed systemic lupus erythematosus associated thrombocytopenia[J]. Chinese Journal of General Practice, 2021, 19(5): 760-762, 793. doi: 10.16766/j.cnki.issn.1674-4152.001910
[2]	HISADA R, KATO M, OHNISHI N, et al. Antiphospholipid score is a novel risk factor for idiopathic osteonecrosis of the femoral head in patients with systemic lupus erythematosus[J]. Rheumatology(Oxford), 2019, 58(4): 645-649. doi: 10.1093/rheumatology/key365
[3]	KANEKO K, CHEN H, KAUFMAN M, et al. Glucocorticoid-induced osteonecrosis in systemic lupus erythematosus patients[J]. Clin Transl Med, 2021, 11(10): e526. DOI: 10.1002/ctm2.526.
[4]	RELLA V, ROTONDO C, ALTOMARE A, et al. Bone involvement in systemic lupus erythematosus[J]. Int J Mol Sci, 2022, 23(10): 5804. doi: 10.3390/ijms23105804
[5]	吴婵媛, 曾小峰. 锝[⁹⁹Tc]亚甲基二膦酸盐注射液治疗类风湿关节炎专家共识[J]. 中华临床免疫和变态反应杂志, 2019, 13(4): 259-262. https://www.cnki.com.cn/Article/CJFDTOTAL-OZHL201904002.htm WU C Y, ZENG X F. Expert consensus of technetium[99Tc]methylene diphosphonate injection for treatment of rheumatoid arthritis[J]. Chinese Journal of Allergy & Clinical Immunology, 2019, 13(4): 259-262. https://www.cnki.com.cn/Article/CJFDTOTAL-OZHL201904002.htm
[6]	赵德伟, 胡永成. 成人股骨头坏死诊疗标准专家共识(2012年版)[J]. 中华关节外科杂志(电子版), 2012, 6(3): 479-484. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHGJ201203031.htm ZHAO D W, HU Y C. Expert consensus on diagnosis and treatment criteria for adult femoral head necrosis(2012)[J]. Chinese Journal of Joint Surgery (Electronic Edition), 2012, 6(3): 479-484. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHGJ201203031.htm
[7]	SHAHARIR S S, CHUA S H, MOHD R, et al. Risk factors for symptomatic Avascular Necrosis(AVN) in a multi-ethnic Systemic Lupus Erythematosus(SLE) cohort[J]. PLoS One, 2021, 16(3): e0248845. DOI: 10.1371/journal.pone.0248845.
[8]	邹瑶, 肖伟, 任翔. 云克治疗类风湿关节炎患者合并骨质疏松的临床疗效观察[J]. 中国骨质疏松杂志, 2021, 27(6): 848-850, 861. doi: 10.3969/j.issn.1006-7108.2021.06.013 ZOU Y, XIAO W, REN X. The clinical observation of 99Tc-MDP in the treatment of rheumatoid arthritis patients with osteoporosis[J]. Chinese Journal of Osteoporosis, 2021, 27(6): 848-850, 861. doi: 10.3969/j.issn.1006-7108.2021.06.013
[9]	王波, 郭会利. 云克联合股骨头坏死愈胶囊治疗早期非创伤性股骨头坏死的临床效果[J]. 实用医学杂志, 2021, 37(10): 1328-1331. doi: 10.3969/j.issn.1006-5725.2021.10.019 WANG B, GUO H L. Analysis of clinical effect and safety of Yunke combined with Gugutou Huaisiyu capsule in the treatment of early non-traumatic femoral head necrosis[J]. The Journal of Practical Medicine, 2021, 37(10): 1328-1331. doi: 10.3969/j.issn.1006-5725.2021.10.019
[10]	曹盼举, 张晓刚, 曹林忠, 等. 从OPG/RANK/RANKL信号调控机制探讨从瘀论治非创伤性股骨头坏死[J]. 中国中医药信息杂志, 2020, 27(4): 4-6. https://www.cnki.com.cn/Article/CJFDTOTAL-XXYY202004002.htm CAO P J, ZHANG X G, CAO L Z, et al. Discussion on Treating Nontraumatic Osteonecrosis of Femoral Head from"Blood Stasis"Based on OPG/RANK/RANKL Signal Regulation Mechanism[J]. Chinese Journal of Information on Traditional Chinese Medicine, 2020, 27(4): 4-6. https://www.cnki.com.cn/Article/CJFDTOTAL-XXYY202004002.htm
[11]	李文茜, 郭永昌, 田亮玉, 等. OPG、RANK、RANKL及血液学指标水平变化与股骨头坏死的相关性研究[J]. 现代医药卫生, 2022, 38(10): 1654-1658, 1662. https://www.cnki.com.cn/Article/CJFDTOTAL-XYWS202210008.htm LI W X, GUO Y C, TIAN L Y, et al. Study on the correlation between the changes of OPG, RANK, RANKL and hematological indexes and osteonecrosis of the femoral head[J]. Journal of Modern Medicine & Health, 2022, 38(10): 1654-1658, 1662. https://www.cnki.com.cn/Article/CJFDTOTAL-XYWS202210008.htm
[12]	ZHENG Y, ZHENG Z H, ZHANG K, et al. Osteonecrosis in systemic lupus erythematosus: systematic insight from the epidemiology, pathogenesis, diagnosis and management[J]. Autoimmun Rev, 2022, 21(2): 102992. DOI: 10.1016/j.autrev.2021.102992.
[13]	曹婷, 韦标方. 骨桥蛋白和趋化素评估非创伤性股骨头坏死的价值[J]. 中国矫形外科杂志, 2021, 29(20): 1853-1857. https://www.cnki.com.cn/Article/CJFDTOTAL-ZJXS202120008.htm CAO T, WEI B F. Clinical value of serum osteopontin and chemerin for evaluating non-traumatic femoral head necrosis[J]. Orthopedic Journal of China, 2021, 29(20): 1853-1857. https://www.cnki.com.cn/Article/CJFDTOTAL-ZJXS202120008.htm
[14]	MAESTRO-PARAMIO L, GARCIA-REY E, BENSIAMAR F, et al. Osteoblast function in patients with idiopathic osteonecrosis of the femoral head: implications for a possible novel therapy[J]. Bone Joint Res, 2021, 10(9): 619-628.
[15]	DONG M, YU X X, CHEN W F, et al. Osteopontin promotes bone destruction in periapical periodontitis by activating the NF-kappaB pathway[J]. Cell Physiol Biochem, 2018, 49(3): 884-898.
[16]	MA M X, TAN Z, LI W Y, et al. Osteoimmunology and osteonecrosis of the femoral head[J]. Bone Joint Res, 2022, 11(1): 26-28.
[17]	SPINELLI F R, GARUFI C, TRUGLIA S, et al. The role of osteopontin as a candidate biomarker of renal involvement in systemic lupus erythematosus[J]. Clin Exp Rheumatol, 2019, 37(6): 899-905.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(2) / Tables(3)

Get Citation

PDF

XML

Article Metrics

Article views (149) PDF downloads(16)

Clinical study of ⁹⁹Technetium-methylenediphosphonate in the treatment of systemic lupus erythematosus complicated with osteonecrosis of the femoral head

doi: 10.16766/j.cnki.issn.1674-4152.003101

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Clinical study of 99Technetium-methylenediphosphonate in the treatment of systemic lupus erythematosus complicated with osteonecrosis of the femoral head

doi: 10.16766/j.cnki.issn.1674-4152.003101

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Export File

Citation

Format

Content

Clinical study of ⁹⁹Technetium-methylenediphosphonate in the treatment of systemic lupus erythematosus complicated with osteonecrosis of the femoral head